These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 10767967)

  • 21. Efficacy of protamine zinc recombinant human insulin for controlling hyperglycemia in dogs with diabetes mellitus.
    Maggiore AD; Nelson RW; Dennis J; Johnson E; Kass PH
    J Vet Intern Med; 2012; 26(1):109-15. PubMed ID: 22211582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin.
    Kusunoki Y; Katsuno T; Myojin M; Miyakoshi K; Ikawa T; Matsuo T; Ochi F; Tokuda M; Murai K; Miuchi M; Hamaguchi T; Miyagawa J; Namba M
    Endocr J; 2013; 60(4):431-9. PubMed ID: 23220949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of acarbose on insulin sensitivity in elderly patients with diabetes.
    Meneilly GS; Ryan EA; Radziuk J; Lau DC; Yale JF; Morais J; Chiasson JL; Rabasa-Lhoret R; Maheux P; Tessier D; Wolever T; Josse RG; Elahi D
    Diabetes Care; 2000 Aug; 23(8):1162-7. PubMed ID: 10937515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of acarbose and voglibose in diabetes patients who are inadequately controlled with basal insulin treatment: randomized, parallel, open-label, active-controlled study.
    Lee MY; Choi DS; Lee MK; Lee HW; Park TS; Kim DM; Chung CH; Kim DK; Kim IJ; Jang HC; Park YS; Kwon HS; Lee SH; Shin HK
    J Korean Med Sci; 2014 Jan; 29(1):90-7. PubMed ID: 24431911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of serum fructosamine and blood glycosylated hemoglobin concentrations for assessment of glycemic control in cats with diabetes mellitus.
    Elliott DA; Nelson RW; Reusch CE; Feldman EC; Neal LA
    J Am Vet Med Assoc; 1999 Jun; 214(12):1794-8. PubMed ID: 10382020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study.
    Lam KS; Tiu SC; Tsang MW; Ip TP; Tam SC
    Diabetes Care; 1998 Jul; 21(7):1154-8. PubMed ID: 9653611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of acarbose treatment on markers of insulin sensitivity and systemic inflammation.
    Rudovich NN; Weickert MO; Pivovarova O; Bernigau W; Pfeiffer AF
    Diabetes Technol Ther; 2011 Jun; 13(6):615-23. PubMed ID: 21488802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Troglitazone combination therapy in obese type 2 diabetic patients poorly controlled with alpha-glucosidase inhibitors.
    Bando Y; Ushiogi Y; Okafuji K; Toya D; Tanaka N; Fujisawa M
    J Int Med Res; 1999; 27(2):53-64. PubMed ID: 10446691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits.
    Hanefeld M; Schaper F
    Expert Rev Cardiovasc Ther; 2008 Feb; 6(2):153-63. PubMed ID: 18248270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A risk-benefit appraisal of acarbose in the management of non-insulin-dependent diabetes mellitus.
    Santeusanio F; Compagnucci P
    Drug Saf; 1994 Dec; 11(6):432-44. PubMed ID: 7727053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.
    Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH; Wolever TM
    Ann Intern Med; 1994 Dec; 121(12):928-35. PubMed ID: 7734015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycemic variability in insulin treated type 2 diabetes with well-controlled hemoglobin A1c and its response to further treatment with acarbose.
    Su JB; Wang XQ; Chen JF; Wu G; Jin Y
    Chin Med J (Engl); 2011 Jan; 124(1):144-7. PubMed ID: 21362322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical experience with acarbose: results of a Canadian multicentre study.
    Rodger NW; Chiasson JL; Josse RG; Hunt JA; Palmason C; Ross SA; Ryan EA; Tan MH; Wolever TM
    Clin Invest Med; 1995 Aug; 18(4):318-24. PubMed ID: 8549019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of the alpha-glucosidase inhibitor acarbose on postprandial serum glucose and insulin concentrations in healthy dogs.
    Robertson J; Nelson R; Kass P; Neal L
    Am J Vet Res; 1999 May; 60(5):541-5. PubMed ID: 10328421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Effect of Acarbose on Glycemic Variability in Patients with Type 2 Diabetes Mellitus Using Premixed Insulin Compared to Metformin (AIM): An Open-Label Randomized Trial.
    Gao F; Ma X; Peng J; Lu J; Lu W; Zhu W; Bao Y; Vigersky RA; Jia W; Zhou J
    Diabetes Technol Ther; 2020 Apr; 22(4):256-264. PubMed ID: 31638433
    [No Abstract]   [Full Text] [Related]  

  • 36. Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in chinese antihyperglycemic agent-naive subjects with type 2 diabetes.
    Zhou J; Li H; Zhang X; Peng Y; Mo Y; Bao Y; Jia W
    Diabetes Technol Ther; 2013 Jun; 15(6):481-8. PubMed ID: 23631607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial.
    Derosa G; Franzetti I; Querci F; D'Angelo A; Maffioli P
    Pharmacotherapy; 2015 Nov; 35(11):983-90. PubMed ID: 26598090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of diabetes mellitus in dogs using isophane insulin penfills and the use of serum fructosamine assays to diagnose and monitor the disease.
    Thoresen SI; Lorenzen FH
    Acta Vet Scand; 1997; 38(2):137-46. PubMed ID: 9257449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Non-insulin-dependent diabetes mellitus associated with nonalcoholic liver cirrhosis: an evaluation of treatment with the intestinal alpha-glucosidase inhibitor acarbose].
    Gentile S; Turco S; Guarino G; Oliviero B; Rustici A; Torella R
    Ann Ital Med Int; 1999; 14(1):7-14. PubMed ID: 10528419
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of beano on the tolerability and pharmacodynamics of acarbose.
    Lettieri JT; Dain B
    Clin Ther; 1998; 20(3):497-504. PubMed ID: 9663365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.